Master screening study to determine individuals with potential trial eligibility for Alzheimer's disease studies
Information about participating in the trial
What are the researchers trying to find out?
No drug or intervention is tested in this study. This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies, as assessed by cognitive and biomarker status.
What your involvement will entail?
- At day 1, participants will undergo a blood test (to assess their concentration of pTau217 in blood) and the International Shopping List Test (ISLT) to evaluate cognitive function. Further information can be obtained from the study team
Further information can be obtained from the study team.
Who can participate in this study?
Who can participate in the study?
To take part in the study, participants must:
- Be between 50 and 90 years old
- Have memory concerns within the last year with or without a previous clinical diagnosis of Mild Cognitive Impairment (MCI) or dementia due to Alzheimer’s disease.
Who cannot participate in the study?
People cannot take part in the study if they have or have experienced:
- Dependency in basic activities of daily living due to cognitive impairment
- Visual or auditory impairment that would prevent performing the cognitive assessments (eyeglasses and hearing aids are permitted)
- Neurological or neurodegenerative condition that may lead to cognitive impairment other than Alzheimer’s disease
- History of severe, clinically significant central nervous system trauma
- A disease that may interfere with the safety or study assessments.
The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.
Information for your doctor
Clinicaltrials.gov identifier
NCT07177352
Study contact information
global-roche-genentech-trials@gene.com
Link to full text
https://clinicaltrials.gov/study/NCT07177352
Study's website
The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) in September 2025.
This document has been reviewed by the pharmaceutical company running this trial.
